-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 11, reporters learned from the Yantai Development Zone Management Committee on the 10th that China's first original antibody-conjugated drug (ADC) new drug-Vidicitor, declared by Rongchang Biopharmaceutical (Yantai) Co.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
Stomach cancer is the second largest cancer in China, with approximately 470,000 new patients in 2020
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
It is reported that, ADC drugs by the monoclonal antibody, and small molecule linker cytotoxic drugs coupled together, both antibody targeting and destruction of small molecule drugs, to complete precision strike on cancer cells, is the world's anti -tumor drugs The key direction of technological development
.
.
By tumor Peking University Hospital of registered clinical trials Wei Dixi trastuzumab Shen Lin, vice president of Tianjin Cancer Hospital, vice president and a co-lead Pakistan to carry out the treatment of gastric cancer showed for 127 had received second-line chemotherapy in HER2 For patients with moderately high expression of advanced or metastatic gastric cancer, the objective remission rate reached 24.
4%, and the median overall survival time reached 7.
9 months
.
4%, and the median overall survival time reached 7.
9 months
.
The approval of vedicitumumab broke the situation of no original domestically produced new drugs in the ADC drug field, and was a milestone in the history of China's independent innovative biological drugs
.
.
In recent years, Yantai, Shandong bio- pharmaceutical health industry rise in 2019 selected the first batch of national strategic emerging industry clusters, Yantai Rongchang biological biomedical enterprises outstanding representatives
.
(Finish)
.
(Finish)
Medical Network, June 11, reporters learned from the Yantai Development Zone Management Committee on the 10th that China's first original antibody-conjugated drug (ADC) new drug-Vidicitor, declared by Rongchang Biopharmaceutical (Yantai) Co.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
Stomach cancer is the second largest cancer in China, with approximately 470,000 new patients in 2020
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
It is reported that, ADC drugs by the monoclonal antibody, and small molecule linker cytotoxic drugs coupled together, both antibody targeting and destruction of small molecule drugs, to complete precision strike on cancer cells, is the world's anti -tumor drugs The key direction of technological development
.
.
By tumor Peking University Hospital of registered clinical trials Wei Dixi trastuzumab Shen Lin, vice president of Tianjin Cancer Hospital, vice president and a co-lead Pakistan to carry out the treatment of gastric cancer showed for 127 had received second-line chemotherapy in HER2 For patients with moderately high expression of advanced or metastatic gastric cancer, the objective remission rate reached 24.
4%, and the median overall survival time reached 7.
9 months
.
4%, and the median overall survival time reached 7.
9 months
.
The approval of vedicitumumab broke the situation of no original domestically produced new drugs in the ADC drug field, and was a milestone in the history of China's independent innovative biological drugs
.
.
In recent years, Yantai, Shandong bio- pharmaceutical health industry rise in 2019 selected the first batch of national strategic emerging industry clusters, Yantai Rongchang biological biomedical enterprises outstanding representatives
.
(Finish)
.
(Finish)
Medical Network, June 11, reporters learned from the Yantai Development Zone Management Committee on the 10th that China's first original antibody-conjugated drug (ADC) new drug-Vidicitor, declared by Rongchang Biopharmaceutical (Yantai) Co.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
Stomach cancer is the second largest cancer in China, with approximately 470,000 new patients in 2020
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
It is reported that, ADC drugs by the monoclonal antibody, and small molecule linker cytotoxic drugs coupled together, both antibody targeting and destruction of small molecule drugs, to complete precision strike on cancer cells, is the world's anti -tumor drugs The key direction of technological development
.
.
By tumor Peking University Hospital of registered clinical trials Wei Dixi trastuzumab Shen Lin, vice president of Tianjin Cancer Hospital, vice president and a co-lead Pakistan to carry out the treatment of gastric cancer showed for 127 had received second-line chemotherapy in HER2 For patients with moderately high expression of advanced or metastatic gastric cancer, the objective remission rate reached 24.
4%, and the median overall survival time reached 7.
9 months
.
4%, and the median overall survival time reached 7.
9 months
.
The approval of vedicitumumab broke the situation of no original domestically produced new drugs in the ADC drug field, and was a milestone in the history of China's independent innovative biological drugs
.
.
In recent years, Yantai, Shandong bio- pharmaceutical health industry rise in 2019 selected the first batch of national strategic emerging industry clusters, Yantai Rongchang biological biomedical enterprises outstanding representatives
.
(Finish)
.
(Finish)
Medical Network, June 11, reporters learned from the Yantai Development Zone Management Committee on the 10th that China's first original antibody-conjugated drug (ADC) new drug-Vidicitor, declared by Rongchang Biopharmaceutical (Yantai) Co.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
, Ltd.
The monoclonal antibody was approved by the China Food and Drug Administration
.
Stomach cancer is the second largest cancer in China, with approximately 470,000 new patients in 2020
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
.
Vidicuzumab is suitable for the treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy for HER2 overexpression, opening up a new path for precise targeted therapy of gastric cancer
.
It is reported that, ADC drugs by the monoclonal antibody, and small molecule linker cytotoxic drugs coupled together, both antibody targeting and destruction of small molecule drugs, to complete precision strike on cancer cells, is the world's anti -tumor drugs The key direction of technological development
.
Tumor tumor tumor.
By tumor Peking University Hospital of registered clinical trials Wei Dixi trastuzumab Shen Lin, vice president of Tianjin Cancer Hospital, vice president and a co-lead Pakistan to carry out the treatment of gastric cancer showed for 127 had received second-line chemotherapy in HER2 For patients with moderately high expression of advanced or metastatic gastric cancer, the objective remission rate reached 24.
4%, and the median overall survival time reached 7.
9 months
.
Hospital hospital hospital4%, and the median overall survival time reached 7.
9 months
.
The approval of vedicitumumab broke the situation of no original domestically produced new drugs in the ADC drug field, and was a milestone in the history of China's independent innovative biological drugs
.
.
In recent years, Yantai, Shandong bio- pharmaceutical health industry rise in 2019 selected the first batch of national strategic emerging industry clusters, Yantai Rongchang biological biomedical enterprises outstanding representatives
.
(Finish)
Pharmaceutical and Health Medicine Pharmaceutical Health and Health Enterprise Enterprise Enterprise .
(Finish)
